| Synopsis: |
Presents evidence that letrozole, anastrozole, and exemestane have proven efficacy as second-line therapy and indicate increased antitumor effects and less toxicity than older aromatase inhibitors and progestins! This reference provides a state-of-the-art assessment of drugs that inhibit the synthesis of estrogens-particularly agents used to treat breast cancer-and demonstrates how the endocrinological effects of the new generation of inhibitors translate into clinical benefits. Highlights recent key research aimed at developing novel reagents and technology to optimize drug therapies and expand their clinical applications.With contributions from over 75 international experts, "Aromatase Inhibition and Breast Cancer" reviews the preclinical development of aromatase inhibitors and their place in the current practice of breast cancer management; Considers aromatase inhibitors for early stages of breast cancer as an adjuvant to surgery; Explains how machine learning techniques accurately identify tumors likely to respond to treatment; Gives an immunohistological evaluation of aromatase protein and RT-PCR measurements at the level of RNA; Describes how model systems based on human material have optimized the use and demonstrated the potential of aromatase inhibitors; Presents the case for employing aromatase inhibitors to treat pubertal gynecomastia, prostate cancer, and benign and malignant endometrial conditions and more! Given the remarkable endocrine effects and the clinical potential of the new generation of aromatase inhibitors, "Aromatase Inhibition and Breast Cancer" is an essential reference for oncologists, endocrinologists, gynecologists, obstetricians, pharmacologists, family physicians, reproductive biologists, and medical school students in these disciplines. |